Show simple item record

dc.contributor.authorAschenbrenner, Diane S.
dc.contributor.departmentSandra R. Berman School of Nursing and Health Professionsen_US
dc.contributor.programNursingen_US
dc.date.accessioned2017-09-27T20:11:37Z
dc.date.available2017-09-27T20:11:37Z
dc.date.issued2017-06
dc.description.abstractThe article reports on drugs that received approval from the U.S. Food and Drug Administration. It notes on the approval given to deflazacort (Emflaza) as treatment for Duchenne muscular dystrophy, the most common type of muscular dystrophy characterized by progressive muscle deterioration and weakness starting in childhood. It cites the approval given to brodalumab (Siliq) as treatment for moderate-to-severe plaque psoriasis, an autoimmune disease that causes patches of red and flaky skin.en_US
dc.description.urihttps://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=123295317&site=eds-live&scope=siteen_US
dc.format.extent2 pagesen_US
dc.genrejournal articlesen_US
dc.identifierdoi:10.13016/M23J3921B
dc.identifier.citationAschenbrenner, D. S. (2017). Drug watch. AJN American Journal Of Nursing, 117(6), 22-23.en_US
dc.identifier.issn0002-936X
dc.identifier.urihttp://hdl.handle.net/11603/5652
dc.language.isoen_USen_US
dc.publisherAmerican Journal of Nursingen_US
dc.titleDRUG Watchen_US
dc.typeTexten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record